Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized 131I Therapy for Graves Disease Hyperthyroidism
ChiCTR-OPd-16008303Phase 4Recruiting
- Sponsor
- Quanzhou First Hospital
- Start
- Apr 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of iodine-131 in Graves' disease (3 arms), sponsored by Quanzhou First Hospital. Primary endpoints: Thyroid volume and Thyroid function. Started Apr 2016; status: recruiting.
02
Drugs
iodine-131
03
Conditions
Graves' disease
Beyond the preview
Go deeper on ChiCTR-OPd-16008303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPd-16008303.